Intercept Pharmaceuticals (Intercept Pharmaceuticals) Days Sales Outstanding : 32.00 (As of Sep. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Intercept Pharmaceuticals Days Sales Outstanding?

Intercept Pharmaceuticals's average Accounts Receivable for the three months ended in Sep. 2023 was $31.1 Mil. Intercept Pharmaceuticals's Revenue for the three months ended in Sep. 2023 was $88.8 Mil. Hence, Intercept Pharmaceuticals's Days Sales Outstanding for the three months ended in Sep. 2023 was 32.00.

The historical rank and industry rank for Intercept Pharmaceuticals's Days Sales Outstanding or its related term are showing as below:

ICPT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 33.1 Med: 46.16 Max: 133.5
Current: 33.1

During the past 13 years, Intercept Pharmaceuticals's highest Days Sales Outstanding was 133.50. The lowest was 33.10. And the median was 46.16.

ICPT's Days Sales Outstanding is not ranked
in the Biotechnology industry.
Industry Median: 72.43 vs ICPT: 33.10

Intercept Pharmaceuticals's Days Sales Outstanding increased from Sep. 2022 (31.57) to Sep. 2023 (32.00).

Intercept Pharmaceuticals Days Sales Outstanding Historical Data

The historical data trend for Intercept Pharmaceuticals's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intercept Pharmaceuticals Days Sales Outstanding Chart

Intercept Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Days Sales Outstanding

Get a 7-Day Free Trial

42.83

46.16

62.08

48.91

35.26

Intercept Pharmaceuticals Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Days Sales Outstanding	Get a 7-Day Free Trial															31.57	31.33	37.33	31.90	32.00

Competitive Comparison of Intercept Pharmaceuticals's Days Sales Outstanding

For the Biotechnology subindustry, Intercept Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Intercept Pharmaceuticals's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intercept Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Intercept Pharmaceuticals's Days Sales Outstanding falls into.

Intercept Pharmaceuticals Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Intercept Pharmaceuticals's Days Sales Outstanding for the fiscal year that ended in Dec. 2022 is calculated as

	Days Sales Outstanding (A: Dec. 2022 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2021 )	+	Accounts Receivable (A: Dec. 2022 ))	/	count )	/	Revenue (A: Dec. 2022 )	*	Days in Period
=	( (28.337	+	26.862)	/	2 )	/	285.71	*	365
=	27.5995					/	285.71	*	365
=	35.26

Intercept Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

	Days Sales Outstanding (Q: Sep. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jun. 2023 )	+	Accounts Receivable (A: Sep. 2023 ))	/	count )	/	Revenue (A: Sep. 2023 )	*	Days in Period
=	( (29.792	+	32.479)	/	2 )	/	88.789	*	365 / 4
=	31.1355					/	88.789	*	365 / 4
=	32.00

Intercept Pharmaceuticals (NAS:ICPT) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Intercept Pharmaceuticals Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Intercept Pharmaceuticals's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Intercept Pharmaceuticals (Intercept Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intercept Pharmaceuticals Inc (NAS:ICPT) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

305 Madison Avenue, Morristown, NJ, USA, 07960

Website

https://www.interceptpharma.com

Intercept Pharmaceuticals Inc is a biotech company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.

Executives

Andrew Saik	officer: EVP & Chief Financial Officer	640 LEE ROAD, CHESTERBROOK PA 19087
M Michelle Berrey	officer: President, R&D and CMO	303A COLLEGE ROAD EAST, PRINCETON NJ 08450
Dagmar Rosa-bjorkeson	director	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Rocco Venezia	officer: Chief Accounting Officer	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FLOOR, NEW YORK NY 10001
Srinivas Akkaraju	director	565 EVERETT AVENUE, PALO ALTO CA 94301
Lisa Defrancesco	officer: SVP, IR & Corp. Affairs	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, FLOOR 37, NEW YORK NY 10001
Linda M Richardson	officer: EVP & Chief Commercial Officer	2505 MERIDIAN PKWY, SUITE 340, C/O CHIMERIX, INC., DURHAM NC 27713
Jared Freedberg	officer: General Counsel and Secretary	300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Bryan Ball	officer: Chief Quality Officer	300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Sandip Kapadia	officer: CFO and Treasurer	450 WEST 15 STREET, SUITE 505, NEW YORK NY 10011
Jason Campagna	officer: Chief Medical Officer	C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, FLOOR 37, NEW YORK NY 10001
Paolo Fundaro	director, 10 percent owner	C/O GENEXTRA S.P.A.,, VIA G. DE GRASSI, 11, MILAN L6 20123
Francesco Micheli	10 percent owner	C/O GENEXTRA S.P.A., VIA G. DE GRASSI, 11, MILAN L6 20124
Genextra S.p.a.	10 percent owner	VIA G. DE GRASSI, 11, MILAN L6 20123
Keith Michael Gottesdiener	director	900 FIFTH AVENUE, #8C, NEW YORK NY 10021